The representative of Novartis said yesterday that “Kisqali” helped women with advanced breast cancer after menopause live longer.
It was the second confirmation data that the Swiss company has distributed a few days earlier. Representatives of the company pytayutsya to convince doctors that “Kisqali” – better helps to fight breast cancer than Pfizer Ibrance.
“Kisqali +” – the drug, according to the doctor, the so-called fulvestrant hormone therapy, compared to other fulvestrant he showed a significant improvement of survival by reducing the risk of death by 28%. About this was announced at a meeting of the European society of medical Oncology in Barcelona.
According to the representative of Novartis, Tiscali is currently the only drug of this type, which shows a positive overall survival.
The Basel firm said this year that “Kisqali +” also increased the survival of women before menopause due to positive hormonal receptor, human epidermal growth factor receptor negative-2 (HR + / HER2-) advanced or metastatic breast cancer.
“These findings give oncologists more data for optimal choice of treatment to their patients with metastatic breast cancer, positive for hormone receptors,” – said in their study, Dennis Slamon, doctor of medical Sciences, University of California (Center for comprehensive cancer treatment Jonsson in Los Angeles).
Sale “Kisqalii” in 2018 amounted to 235 million dollars, far less than the 4.1 billion dollars for Ibrance, as the first to market the drug Pfizer covered the lion’s share of women with metastatic HR + / HER2-.
However, the survey conducted by Refinitiv showed that analysts expect that in the “Kisqalii” will bring about 130,000 dollars per year, and sales will be about $ 1.2 billion by 2024.